Insider Selling: Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Sells 7,901 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley L. Campbell sold 7,901 shares of the firm’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $11,083,175. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Amicus Therapeutics Price Performance

FOLD opened at $10.99 on Friday. The stock’s 50-day moving average price is $11.13 and its 200 day moving average price is $10.61. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The firm has a market cap of $3.26 billion, a price-to-earnings ratio of -32.32 and a beta of 0.68. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.05). The business had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 21.21% and a negative return on equity of 17.03%. The business’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.15) earnings per share. As a group, sell-side analysts expect that Amicus Therapeutics, Inc. will post -0.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

FOLD has been the topic of a number of recent research reports. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target on the stock. Guggenheim boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday. Bank of America lifted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. dropped their target price on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a report on Friday, August 16th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.50.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. purchased a new stake in Amicus Therapeutics during the 2nd quarter worth about $8,386,000. M&G Plc lifted its stake in Amicus Therapeutics by 12.4% in the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares during the last quarter. Edgestream Partners L.P. grew its holdings in Amicus Therapeutics by 1,290.4% during the 1st quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock worth $3,183,000 after acquiring an additional 250,734 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of Amicus Therapeutics by 7.8% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after purchasing an additional 7,304 shares during the last quarter. Finally, Fiera Capital Corp raised its holdings in shares of Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after purchasing an additional 58,113 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.